Colin J. Meyer

6.7k total citations · 2 hit papers
82 papers, 5.2k citations indexed

About

Colin J. Meyer is a scholar working on Molecular Biology, Biochemistry and Nephrology. According to data from OpenAlex, Colin J. Meyer has authored 82 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 12 papers in Biochemistry and 10 papers in Nephrology. Recurrent topics in Colin J. Meyer's work include Genomics, phytochemicals, and oxidative stress (32 papers), Mitochondrial Function and Pathology (9 papers) and Genetic Neurodegenerative Diseases (6 papers). Colin J. Meyer is often cited by papers focused on Genomics, phytochemicals, and oxidative stress (32 papers), Mitochondrial Function and Pathology (9 papers) and Genetic Neurodegenerative Diseases (6 papers). Colin J. Meyer collaborates with scholars based in United States, Australia and United Kingdom. Colin J. Meyer's co-authors include Melissa Krauth, Melanie Chin, Pablo E. Pérgola, Janet Wittes, Robert D. Toto, Paul Audhya, Heidi Christ‐Schmidt, Glenn M. Chertow, Stacey Ruiz and Angie Goldsberry and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Colin J. Meyer

80 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

2013 784 citations Melanie Chin, Angie Goldsberry et al. profile →
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

2011 707 citations Pablo E. Pérgola, Philip Raskin et al. profile →

Peers

Countries citing papers authored by Colin J. Meyer

Since Specialization

Citations

This map shows the geographic impact of Colin J. Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin J. Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin J. Meyer more than expected).

Fields of papers citing papers by Colin J. Meyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin J. Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin J. Meyer. The network helps show where Colin J. Meyer may publish in the future.

Co-authorship network of co-authors of Colin J. Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Colin J. Meyer. A scholar is included among the top collaborators of Colin J. Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin J. Meyer. Colin J. Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data 2023 ·Annals of Clinical and Translational Neurology ·David R. Lynch, Angie Goldsberry, Christian Rummey, Jennifer Farmer, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Susan Perlman, S. H. Subramony, George Wilmot, Theresa A. Zesiewicz, Lisa A. Weissfeld, Colin J. Meyer	24
2	Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension 2022 ·Movement Disorders ·David R. Lynch, Melanie Chin, Sylvia Boesch, Martin B. Delatycki, Paola Giunti, Angie Goldsberry, J. Chad Hoyle, Caterina Mariotti, Katherine D. Mathews, Wolfgang Nachbauer, Megan O’Grady, Susan Perlman, S. H. Subramony, George Wilmot, Theresa A. Zesiewicz, Colin J. Meyer	55
3	Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study) 2020 ·Annals of Neurology ·David R. Lynch, Melanie Chin, Martin B. Delatycki, S. H. Subramony, Manuela Corti, J. Chad Hoyle, Sylvia Boesch, Wolfgang Nachbauer, Caterina Mariotti, Katherine D. Mathews, Paola Giunti, George Wilmot, Theresa A. Zesiewicz, Susan Perlman, Angie Goldsberry, Megan A. O’Grady, Colin J. Meyer	177
4	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease 2018 ·Journal of Diabetes and its Complications ·Glenn M. Chertow, Gerald B. Appel, Geoffrey A. Block, Melanie Chin, Daniel W. Coyne, Angie Goldsberry, Kamyar Kalantar‐Zadeh, Colin J. Meyer, Mark E. Molitch, Pablo E. Pérgola, Philip Raskin, (unknown), Bruce Spinowitz, Stuart M. Sprague, Peter Rossing	11
5	The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling 2017 ·Free Radical Biology and Medicine ·Kristen J. Bubb, Cindy Kok, Owen Tang, (unknown), Åsa Birna Birgisdottir, (unknown), Rebecca H. Ritchie, Ravinay Bhindi, Scott A. Reisman, Colin J. Meyer, Keith W. Ward, Keyvan Karimi Galougahi, Gemma A. Figtree	33
6	A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma 2017 ·Annals of Oncology ·(unknown), F. Stephen Hodi, Dmitry I. Gabrilovich, Melanie Chin, Geoffrey T. Gibney, (unknown), René González, (unknown), Joseph Markowitz, Eric D. Whitman, Colin J. Meyer, April K.S. Salama	5
7	Abstract 15540: NRF2 Upregulation Attenuates Post-Infarct Ventricular Remodeling by Modifying Redox Signalling 2016 ·Circulation ·Kristen J. Bubb, Cindy Kok, Owen Tang, (unknown), Thomas Hansen, Rebecca H. Ritchie, Ravinay Bhindi, Scott A. Reisman, Colin J. Meyer, Keith W. Ward, Keyvan Karimi Galougahi, Gemma A. Figtree	1
8	Dihydro-CDDO-trifluoroethyl amide suppresses inflammatory responses in macrophages via activation of Nrf2 2014 ·Biochemical and Biophysical Research Communications ·Bin Li, (unknown), Yimu Lai, Joseph S. Janicki, Keith W. Ward, Colin J. Meyer, Xing Li Wang, Dongqi Tang, Taixing Cui	19
9	The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease 2013 ·Xenobiotica ·Mohammad A. Aminzadeh, Scott A. Reisman, Nosratola D. Vaziri, Mahyar Khazaeli, Jun Yuan, Colin J. Meyer	74
10	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas 2012 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer J. Wheler, Donald P. Lawrence, Joseph P. Eder, Colin J. Meyer, Deborah A. Ferguson, James W. Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Küfe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube	197
11	Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1 2011 ·American Journal of Physiology-Renal Physiology ·Qing Wu, Yanxia Wang, (unknown), Colin J. Meyer, W. Christian Wigley, Deborah A. Ferguson, Eric Grossman, Jianlin Chen, Xin Zhou, John Hartono, Pamela D. Winterberg, Bo Chen, (unknown), Christopher Y. Lu	136
12	Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD 2011 ·American Journal of Nephrology ·Pablo E. Pérgola, Melissa Krauth, Jesse W. Huff, Deborah A. Ferguson, Stacey Ruiz, Colin J. Meyer, David G. Warnock	197
13	Role of Peroxisome Proliferator-Activated Receptor-γ and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia 2010 ·Cancer Research ·Twee Tsao, Steven M. Kornblau, Stephen Safe, Julie C. Watt, Vivian Ruvolo, Wenjing Chen, Yihua Qiu, Kevin R. Coombes, Zhenlin Ju, Maen Abdelrahim, Wendy Schober, Xiaoyang Ling, Dimitris Kardassis, Colin J. Meyer, Aaron D. Schimmer, Hagop M. Kantarjian, Michael Andreeff, Marina Konopleva	39
14	Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer 2010 ·Clinical Cancer Research ·Srinivas Nagaraj, Je-In Youn, Hannah Weber, Cristina Iclozan, Lily Lu, Matthew J. Cotter, Colin J. Meyer, Carlos Becerra, Mayer Fishman, Scott Antonia, Michael B. Sporn, Karen T. Liby, Bhupendra Rawal, Ji‐Hyun Lee, Dmitry I. Gabrilovich	225
15	The Synthetic Triterpenoid, CDDO-Me, Modulates the Proinflammatory Response to In Vivo Lipopolysaccharide Challenge 2010 ·Journal of Interferon & Cytokine Research ·Jeffery J. Auletta, (unknown), Byung‐Gyu Kim, Colin J. Meyer, John J. Letterio	27
16	Apoptotic Activity and Mechanism of 2-Cyano-3,12-Dioxoolean-1,9-Dien-28-Oic-Acid and Related Synthetic Triterpenoids in Prostate Cancer 2008 ·Cancer Research ·Marc L. Hyer, Ranxin Shi, Maryla Krajewska, Colin J. Meyer, Irina V. Lebedeva, Paul B. Fisher, John C. Reed	52
17	Phase I clinical pharmacokinetics of RTA 744 (berubicin(B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-ol) 2007 ·Molecular Cancer Therapeutics ·(unknown), Charles A. Conrad, Mary Johansen, (unknown), (unknown), Colin J. Meyer, Waldemar Priebe, Timothy Madden	2
18	Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies 2007 ·Molecular Cancer Therapeutics ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Donald P. Lawrence, Jennifer Wheeler, Joseph P. Eder, (unknown), James W. Mier, Marina Konopleva, Sergej Konoplev, Sühendan Ekmekçioglu, Michael Andreeff, (unknown), Donald Küfe, Colin J. Meyer, Geoffrey I. Shapiro, Bruce J. Dezube	4
19	Gene expression profiles in HCT116 and HT29 cells exposed to RTA 502 lead to insights into the mechanism of action 2007 ·Cancer Research ·Teresa Kosakowska‐Cholody, Wieslaw M. Cholody, (unknown), Colin J. Meyer, Christopher J. Michejda	2
20	Localization of neuropeptide Y and its flanking peptide in human renal tissue 1994 ·Peptides ·Eric Grouzmann, (unknown), Colin J. Meyer, M. C. Osterheld, Michel Burnier, Hans R. Brunner, Bernard Waeber	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact